文献速递头颈外科

使用术中甲状旁腺激素监测管理甲状腺切除术后低钙血症

Management of Postthyroidectomy Hypocalcemia Using Intraoperative Parathyroid Hormone Monitoring.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2025-01-01

这项回顾性队列研究纳入217例全切或补充性甲状腺切除术患者,评估术中甲状旁腺激素(ioPTH)监测用于术后补充治疗分层的价值;预测任何术后补充的最佳模型为基线至即刻ioPTH下降30%,总体准确率78.20%;预测使用碳酸钙加骨化三醇补充的最佳模型为即刻ioPTH水平22 pg/mL,总体准确率73.91%。

要点

  • 基线至即刻ioPTH下降30%预测任何术后补充,总体准确率78.20%,敏感度74.78%,特异度82.29%。
  • 即刻ioPTH 22 pg/mL预测碳酸钙加骨化三醇补充,总体准确率73.91%,敏感度70.00%,特异度78.18%。
  • 217例中98例(45.2%)发生暂时性甲状旁腺功能减退,2例发生永久性甲状旁腺功能减退。

核心结论

  • 阈值分析结果表明ioPTH可用于指导术后补充治疗。
  • ioPTH也可能有助于术中指导甲状旁腺自体移植,可能降低永久性甲状旁腺功能减退的风险。

研究设计与样本

  • 回顾性队列研究,在单一学术中心开展,纳入2021年1月至2022年12月接受全切或补充性甲状腺切除术的患者,分析于2024年7月完成。
  • 为完成计划的阈值分析,额外纳入2020年1月至2020年12月及2023年1月至2023年6月手术并出院时接受碳酸钙和骨化三醇补充的患者。
  • 排除同期行甲状旁腺切除术或侧颈淋巴结清扫的患者。
  • 共纳入217例患者,平均(SD)年龄49.94(15.56)岁,女性193例(89%),黑人15例(7%),白人197例(91%)。

主要发现

  • 100例(46.1%)未接受补充治疗,61例(28.1%)接受碳酸钙,56例(25.8%)接受碳酸钙加骨化三醇。
  • 98例(45.2%)发生暂时性甲状旁腺功能减退,2例发生永久性甲状旁腺功能减退。
  • 预测任何术后补充的最佳模型为基线至即刻ioPTH下降30%,总体准确率78.20%(敏感度74.78%,特异度82.29%)。
  • 预测使用碳酸钙加骨化三醇补充的最佳模型对应即刻ioPTH水平22 pg/mL,总体准确率73.91%(敏感度70.00%,特异度78.18%)。

关键数值与推荐

  • 所有患者术前在术前区域采集基线PTH水平,甲状腺切除后即刻及10分钟后额外采集ioPTH水平。
  • 结局分组按补充治疗层级确定:未补充对照组、仅碳酸钙组、碳酸钙加骨化三醇组。
  • 采用逻辑回归模型分析ioPTH预测术后补充治疗层级的阈值。

临床怎么用

  • 作者认为ioPTH可用于指导术后补充治疗。
  • 作者认为ioPTH也可能作为术中指导甲状旁腺自体移植的辅助手段,可能降低永久性甲状旁腺功能减退的风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Postthyroidectomy hypoparathyroidism is typically diagnosed with low serum calcium levels, often requiring patients to remain in the hospital for appropriate treatment. Given the short half-life of parathyroid hormone (PTH), can hypoparathyroidism be diagnosed intraoperatively when re-exploration and autotransplant are still possible? OBJECTIVE: To determine whether intraoperative parathyroid hormone monitoring (ioPTH) permits the stratification of patients into appropriate tiers for postoperative supplementation. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included patients undergoing total or completion thyroidectomy and was conducted at a single academic center from January 2021 and December 2022. Analysis was completed in July 2024. To complete the planned threshold analysis, additional patients who had surgery between January 2020 to December 2020 and January 2023 to June 2023 and were discharged with calcium carbonate and calcitriol supplementation were included. Patients undergoing concomitant parathyroidectomy or lateral neck dissection were excluded. EXPOSURES: All patients had a baseline PTH level drawn in the preoperative area. Additional ioPTH levels were drawn immediately and 10 minutes after thyroid excision. The exposure of interest was the absolute and relative change from baseline to immediate and 10-minute ioPTH. MAIN OUTCOMES AND MEASURES: Outcome groups were determined by supplementation tier. A control group that received no supplementation was compared with the groups that received calcium carbonate only or calcium carbonate plus calcitriol. Logistic regression models were used to analyze the threshold at which ioPTH could predict postoperative supplementation tier. RESULTS: Of the 217 patients included (mean [SD] age, 49.94 [15.56] years; 193 female individuals [89%]; 15 patients [7%] were Black, and 197 patients [91%] were White), 100 (46.1%) received no supplementation, 61 (28.1%) received calcium carbonate, and 56 (25.8%) received calcium carbonate plus calcitriol. Ninety eight (45.2%) experienced temporary hypoparathyroidism, while 2 patients developed permanent hypoparathyroidism. The best model to predict any postoperative supplementation used a 30% decrease from baseline to immediate ioPTH with an overall accuracy rate of 78.20% (sensitivity, 74.78%; specificity, 82.29%). The best model to predict use of calcium carbonate plus calcitriol supplementation corresponded to an immediate ioPTH level of 22 pg/mL, with an overall accuracy rate of 73.91% (sensitivity, 70.00%; specificity, 78.18%). CONCLUSIONS AND RELEVANCE: The results of the threshold analysis demonstrated the utility of ioPTH in guiding postoperative supplementation. ioPTH may also be a useful adjunct in guiding parathyroid autotransplant intraoperatively, potentially reducing the risk of permanent hypoparathyroidism.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Reagan AM, Robson Chase ME, Mangino AA, et al. Management of Postthyroidectomy Hypocalcemia Using Intraoperative Parathyroid Hormone Monitoring. JAMA Otolaryngol Head Neck Surg. 2025. PMID: 40839277. doi:10.1001/jamaoto.2025.2370

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。